ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1325

The Risks of Osteoporotic Fracture After Lung Transplant: A Retrospective Cohort Study at an International Transplant Center

Adil Vural1, Sarah Keller2, Neel Tapryal3, Komal Mushtaq4, Hassan Shaheen1, Chao Zhang2, Marie Budev2, Abby Abelson2 and Chad Deal5, 1Cleveland Clinic, Westlake, OH, 2Cleveland Clinic, Cleveland, OH, 3Cleveland Clinic, Rocky River, OH, 4Cleveland Clinic, Fairview Park, OH, 5Cleveland Clinic, Shaker Heights, OH

Meeting: ACR Convergence 2022

Keywords: Bone density, Dual energy x-ray absorptiometry (DEXA), osteopenia, osteoporosis, pulmonary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Osteoporotic fractures are a well-known complication of lung transplant (LT) and can significantly impact the quality of life of LT recipients. Although much is known about the risk factors associated with osteoporosis and fragility fractures in the general population, there is a lack of data specifically addressing risk factors for osteoporotic fracture in the LT population. Furthermore, there are no universal guidelines that can direct management of osteoporosis and bone density loss in the LT population. The aim of this study was to determine the incidence of osteoporotic fractures among patients with end-stage lung disease prior to and following LT and to identify the potential factors that increase the risk of fractures after LT.

Methods: This retrospective, cohort study was conducted at a large, international transplant center and included all patients over age 18 who underwent either single or double LT from January 1, 2010-December 31, 2013. We conducted an extensive chart review using electronic medical records data. We excluded patients who expired within the first year following LT as well as patients who had undergone prior LT. Study endpoints included: incidence of vertebral and non-vertebral fractures after LT and potential risk factors for post-LT fractures as identified by clinicians. A secondary endpoint included the effect of osteoporosis medications on fracture incidence post-LT. We used logistic regression modeling to understand the relationships between potential risk factors and post-LT fracture.

Results: A total of 432 adults underwent LT between January 1, 2010 and December 2013; 374 patients remained in the cohort after the exclusion criteria were applied (median age, 61; 67% male, 88% white). The two most common indications for LT were idiopathic pulmonary fibrosis (48%) followed by chronic obstructive pulmonary disease (23%). Prior to LT, 128 patients had osteopenia and 84 patients had osteoporosis. The prevalence of fracture pre-LT was 45 (12%) and the most common type of fracture was vertebral (20, 44%). 83 fractures occurred (22%) occurred after LT and 46 of these were vertebral. The median time to post-LT fracture was 887 days. The odds ratio of having a post-LT fracture with pre-LT diagnosis of osteopenia was 2.44 (95% CI 1.29-4.62,p=0.006) vs normal bone mass. 153 patients (41%) were treated with osteoporosis medications prior to LT, most commonly alendronate (61%). Following LT 227 patients (61%) were treated with osteoporosis medications, most commonly alendronate (51%) followed by denosumab (24%). 27 out of all 128 fractures occurred among patients on osteoporosis medications; 101 fractures (78.9%) (pre- and post-LT) occurred in patients not on osteoporosis medications.

Conclusion: These data demonstrate the incidence of post-LT fracture is high (22%). Furthermore, the odds of post-LT fracture for patients who had pre-LT osteopenia was 2.44. Interestingly, pre-LT fracture, diagnosis of osteoporosis, and steroid use were not associated with an increased risk of post-LT fracture. Our findings support that ongoing vigilance is required to prevent fragility fractures in the LT population and that there is a need to develop universal LT osteoporosis management guidelines.

Supporting image 1

Table 1. Summary of study population characteristics.

Supporting image 2

Table 2. Summary of osteopenia/osteoporosis prevalence and fragility fractures before and after transplant.

Supporting image 3

Table 3. Post-transplant fragility fracture predictors assessment.


Disclosures: A. Vural, None; S. Keller, Merck/MSD; N. Tapryal, None; K. Mushtaq, None; H. Shaheen, None; C. Zhang, None; M. Budev, None; A. Abelson, None; C. Deal, Radius Health, Amgen, Inc., Eli Lilly.

To cite this abstract in AMA style:

Vural A, Keller S, Tapryal N, Mushtaq K, Shaheen H, Zhang C, Budev M, Abelson A, Deal C. The Risks of Osteoporotic Fracture After Lung Transplant: A Retrospective Cohort Study at an International Transplant Center [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-risks-of-osteoporotic-fracture-after-lung-transplant-a-retrospective-cohort-study-at-an-international-transplant-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risks-of-osteoporotic-fracture-after-lung-transplant-a-retrospective-cohort-study-at-an-international-transplant-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology